Assessment of intensive statin therapy in hospitalized patients with acute myocardial infarction and its influence factors / 实用医学杂志

Objective To explore the status quo of intensive statin therapy in hospitalized patients with acute myocardial infarction (AMI) from 2001 to 2011 and analyze its influence factors.Methods We obtained in-formation of AMI patients in 2001,2006,and 2011 from their medical record. Intensive statin therapy was defined as statin regiments with expected LDL-C lowering of at least 40%.Results Among 767 patientswith definite dosage of statin,the use frequencyof intensive statin increased from 0%in 2001 to 60.77% in 2006,and 88.71% in 2011 (P0.05). Conclusions The use frequency of intensive stain therapy among AMI patientsincreasesyear by year and it is affected by sex,risk factors,history of disease and type of infarction.

Bleeding risk of short-term intensive statin therapy after coronary artery bypass grafting / 临床外科杂志

Objective To observe the bleeding risk of short-term intensive statin therapy after coronary artery bypass grafting. Methods A total of 240 patients treated with coronary artery bypass grafting were randomly divided into group A(experimental group)and group B(control group). All pa-tients were normalized to conventional treatment and they were given low molecular weight heparin for an-ticoagulant therapy during the perioperative period. Patients in group A were given 40 mg of atorvastatin before surgery,and 40 mg of atorvastatin every night for one month after the surgery. Patients in group B were given 10 mg of atorvastatin every night during the treatment. One month after the operation,platelet aggregation rate and bleeding events of patients were compared. Results There were significant differ-ences in maximum platelet aggregation rate[(14. 5 ± 3. 7)% vs(38. 1 ± 7. 4)% ,P < 0. 05],inhibition rate of platelet aggregation[(79. 5 ± 4. 3)% vs(50. 8 ± 10. 2)% ,P < 0. 05],and incidence of postopera-tive bleeding[27. 5% vs 12. 5% ,P < 0. 05]between group A and B,respectively. Conclusion Short-term intensive statin therapy can increase the bleeding risk after coronary artery bypass grafting.

Effect of intensive statin on platelet activity and inflammation factors in rat with myocardial infarction / 重庆医学

Objective To explore the effect of intensive statin on platelet activity and inflammation factors 24 h after rat myocar‐dial infarction .Methods Seventy Sprague‐Dawley rats were randomly divided into five groups (n= 14):Sham‐operated group (SHAM group);AMI group(control group) ,general group;intensive statin therapy group ;general and intensive statin therapy group;established AMI rat model by ligation of left anterior descending branch of coronary artery .The general group ,general and intensive statin therapy group was fed atorvastatin by 10 mg · kg -1 · d-1 with distilled water 2 mL by intragastric gavage daily for two weeks .The intensive statin therapy group ,general and intensive statin therapy group was fed atorvastatin by 50 mg/kg with distilled water 2 mL by intragastric gavage 12 h before surgery .Serum PAC‐1 ,CD62p ,TNF‐α,hs‐CRP was measured at the time of 24 h of postoperation .Results TNF‐α,hs‐CRP ,PAC‐1 and CD62p levels in control group were significantly higher than the SHAM group and intensive statin group 24 h after the LADS were ligated(P 0 .05);and there was no significant difference between normal group and control group in all the four factors (P>0 .05) .Conclusion Intensive statin therapy before acute myocardial infarction could decrease the level of inflammation factors and inhibit platelet activity postop‐eration .

The short-term efficacy and safety of intensive statin therapy in acute coronary syndrome after percutaneous coronary intervention / 中国介入心脏病学杂志

Objective This study was designed to evaluate the short-term effect and safety of 80 mg/d atorvastatin treating on ACS patients with interventional therapy in China. Methods From August 2002 to March 2014,1746 ACS patients accepting 80mg/d atorvastatin treatment were enrolled from three province hospital. All patients were divided into three groups, 886 patients in group A with 80mg/d atorvastatin treating for 4 weeks, 562 patients in group B with 80mg/d atorvastatin treating for 8 weeks, and 298 patients in group C with 80mg/d atorvastatin treating for 12 weeks after discharge. Blood lipid level, hepatic function, renal function and creatine kinase level were tested on 4th, 8th, 12th week. Results The percentage of patients reacting lipid levels was 85.0%in group A, 86.1%in group B, 94.0%in group C and 86.9%in total. The rate of ALT/AST exceed two times of normal upper level in group A was 1.6%, in group B was 1.8%and in group C was 1.0%.The symptom of joint and muscle pain in group A was 6.3%, group B was 1.4%, group C was 2.7%. The elevation of creatine kinase in group A was 0.8%, in group B was 0.5%, and 0%in group C. The symptom of abdomen discomfort in group A was 2.3%, group B was 2.5%and group C was 4.0%. The complaint of other symptoms was 3.2%in group A, 2.1%in group B, 1.7%in group C. Conclusions Accepting 80 mg/d atorvastatin treating for ACS patients with interventional therapy is effective and safe in short term.